Radiation therapy clinic software provider RaySearch Laboratories highlighted a net sales increase of 21% in its 2023 annual report, posting 1.02 billion Swedish krona ($93.2 million U.S.).
The Stockholm, Sweden-based company also reported an operating loss/profit of 114.9 million Swedish krona ($10.5 million U.S.), an increase of 169% over 2022. Operating margin also increased to 11.2% in 2023, up from 5.1% in 2022.
CEO and founder Johan Löf attributed the results to the company's four core products: RayStation, RayCare, RayCommand, and RayIntelligence, and long-term agreements and milestones that include deeper collaboration with MedAustron in Austria toward the RaySearch integrated product RayWorld and new orders in the Asia-Pacific region. Lof also noted the role of RayCare in the new Australian Brag Centre for Proton Therapy and Research. In addition, RaySearch's product portfolio was broadened with the addition of the Pharmacolog AB product, DrugLog.
